Enrollment remains on track in Phase 2 pivotal portion of PYNNACLE trial evaluating rezatapopt as monotherapy in platinum-resistant/refractory ...
10 小时
PMV Pharmaceuticals, Inc.: PMV Pharmaceuticals Reports Full Year 2025 Financial Results and ...
Enrollment remains on track in Phase 2 pivotal portion of PYNNACLE trial evaluating rezatapopt as monotherapy in platinum-resistant/refractory ovarian cancer patients with a TP53 Y220C mutationRezatap ...
Cells in our immune system are best known for providing security against external invaders such as bacteria and viruses. These immune cells also guard against internal threats, including cancerous ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果